These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 16172194)

  • 1. Antiestrogen-resistant human breast cancer cells require activated protein kinase B/Akt for growth.
    Frogne T; Jepsen JS; Larsen SS; Fog CK; Brockdorff BL; Lykkesfeldt AE
    Endocr Relat Cancer; 2005 Sep; 12(3):599-614. PubMed ID: 16172194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells.
    Bartucci M; Morelli C; Mauro L; Andò S; Surmacz E
    Cancer Res; 2001 Sep; 61(18):6747-54. PubMed ID: 11559546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiestrogen ICI 182,780 decreases proliferation of insulin-like growth factor I (IGF-I)-treated MCF-7 cells without inhibiting IGF-I signaling.
    Varma H; Conrad SE
    Cancer Res; 2002 Jul; 62(14):3985-91. PubMed ID: 12124331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein Kinase C alpha is a marker for antiestrogen resistance and is involved in the growth of tamoxifen resistant human breast cancer cells.
    Frankel LB; Lykkesfeldt AE; Hansen JB; Stenvang J
    Breast Cancer Res Treat; 2007 Aug; 104(2):165-79. PubMed ID: 17061041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retinoic acid-induced growth arrest of MCF-7 cells involves the selective regulation of the IRS-1/PI 3-kinase/AKT pathway.
    del Rincón SV; Rousseau C; Samanta R; Miller WH
    Oncogene; 2003 May; 22(22):3353-60. PubMed ID: 12776186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
    deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
    Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells.
    Jordan NJ; Gee JM; Barrow D; Wakeling AE; Nicholson RI
    Breast Cancer Res Treat; 2004 Sep; 87(2):167-80. PubMed ID: 15377841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer.
    Chu I; Blackwell K; Chen S; Slingerland J
    Cancer Res; 2005 Jan; 65(1):18-25. PubMed ID: 15665275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of the SNT-1/FRS2 phosphotyrosine binding domain inhibits activation of MAP kinase and PI3-kinase pathways and antiestrogen resistant growth induced by FGF-1 in human breast carcinoma cells.
    Manuvakhova M; Thottassery JV; Hays S; Qu Z; Rentz SS; Westbrook L; Kern FG
    Oncogene; 2006 Sep; 25(44):6003-14. PubMed ID: 16682955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of a human breast cancer cell line, MCF-7/RU58R-1, resistant to the pure antiestrogen RU 58,668.
    Fog CK; Christensen IJ; Lykkesfeldt AE
    Breast Cancer Res Treat; 2005 May; 91(2):133-44. PubMed ID: 15868441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Caveolin-1 inhibits cell detachment-induced p53 activation and anoikis by upregulation of insulin-like growth factor-I receptors and signaling.
    Ravid D; Maor S; Werner H; Liscovitch M
    Oncogene; 2005 Feb; 24(8):1338-47. PubMed ID: 15592498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upregulation of PKC-delta contributes to antiestrogen resistance in mammary tumor cells.
    Nabha SM; Glaros S; Hong M; Lykkesfeldt AE; Schiff R; Osborne K; Reddy KB
    Oncogene; 2005 Apr; 24(19):3166-76. PubMed ID: 15735693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Insulin-like growth factor receptor I signaling in a breast cancer cell line].
    Mejía W; Castro C; Umaña A; de Castro C; Riveros T; Sánchez-Gómez M
    Biomedica; 2010; 30(4):551-8. PubMed ID: 21713359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.
    Kurokawa H; Arteaga CL
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4436s-4442s; discussion 4411s-4412s. PubMed ID: 11916237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of the phosphatidylinositol 3-kinase/Akt pathway prevents radiation-induced apoptosis in breast cancer cells.
    Söderlund K; Pérez-Tenorio G; Stål O
    Int J Oncol; 2005 Jan; 26(1):25-32. PubMed ID: 15586221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
    Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
    BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CCAAT/Enhancer binding protein delta (c/EBPdelta) regulation and expression in human mammary epithelial cells: I. "Loss of function" alterations in the c/EBPdelta growth inhibitory pathway in breast cancer cell lines.
    Sivko GS; DeWille JW
    J Cell Biochem; 2004 Nov; 93(4):830-43. PubMed ID: 15389879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IGF-1 activates hEAG K(+) channels through an Akt-dependent signaling pathway in breast cancer cells: role in cell proliferation.
    Borowiec AS; Hague F; Harir N; Guénin S; Guerineau F; Gouilleux F; Roudbaraki M; Lassoued K; Ouadid-Ahidouch H
    J Cell Physiol; 2007 Sep; 212(3):690-701. PubMed ID: 17520698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tamoxifen and ICI 182,780 increase Bcl-2 levels and inhibit growth of breast carcinoma cells by modulating PI3K/AKT, ERK and IGF-1R pathways independent of ERalpha.
    Lam L; Hu X; Aktary Z; Andrews DW; Pasdar M
    Breast Cancer Res Treat; 2009 Dec; 118(3):605-21. PubMed ID: 19002577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway.
    Yasumaru M; Tsuji S; Tsujii M; Irie T; Komori M; Kimura A; Nishida T; Kakiuchi Y; Kawai N; Murata H; Horimoto M; Sasaki Y; Hayashi N; Kawano S; Hori M
    Cancer Res; 2003 Oct; 63(20):6726-34. PubMed ID: 14583467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.